Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer

详细信息    查看全文

• 作者：Takayuki Suzuki ; Hideaki Shimada…
• 关键词：Serum p53 antibody ; Rectal cancer ; Liver metastases ; Lung metastases
• 刊名：Clinical Journal of Gastroenterology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：9
• 期：2
• 页码：55-58
• 全文大小：2,637 KB
• 参考文献：1.Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by task force of Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRef PubMed
  2.Shimada H, Ochiai T, Nomura F, Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multi-institutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRef PubMed
  3.Zhang J, Xu Z, Yu L, Chen M, Li K, et al. Assessment of the potential diagnostic value of serum p53 antibody for cancer: a meta-analysis. PLoS One. 2014;9:e99255. doi:10.​1371/​journal.​pone.​0099255 .CrossRef PubMed PubMedCentral
  4.Yamaguchi T, Takii Y, Maruyama S. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today. 2014;44:1529–35.CrossRef PubMed
  5.Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164–8.CrossRef PubMed
  6.Takeda A, Shimada H, Nakajima K, et al. Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol. 2001;6:45–9.CrossRef PubMed
  7.Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2000;132:41–7.CrossRef
  8.Tang R, Yeh CY, Wang JY, et al. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol. 2009;16:2516–23.CrossRef PubMed
  9.Kawahara H, Watanabe K, Enomoto H, et al. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer. Anticancer Res. 2013;33:2221–5.PubMed
  10.Shimada H, Okazumi S, Takeda A, Nabeya Y, Matsubara H, Funami Y, et al. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today. 2001;31:591–6.CrossRef PubMed
  11.Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRef PubMed
  12.Lechpammer M, Lukac J, Lechpammer S, Kovacević D, Loda M, Kusić Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis. 2004;19:114–20.CrossRef PubMed
  13.Shimada H, Nagata M, Nabeya Y, et al. Paradoxical changing of serum p53 antibody titers during chemotherapy for a stage IV esophageal squamous cell carcinoma. Int Canc Conf J. 2014;44:1957–61.
  
• 作者单位：Takayuki Suzuki (1)
  Hideaki Shimada (1)
  Mitsunori Ushigome (1)
  Junichi Koike (1)
  Kimihiko Funahashi (1)
  Tetsuo Nemoto (2)
  Hironori Kaneko (1)
  
  1. Department of Surgery, School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan
  2. Department of Pathology, Toho University School of Medicine, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541, Japan
  
• 刊物主题：Gastroenterology; Hepatology; Abdominal Surgery; Colorectal Surgery; Surgical Oncology;
• 出版者：Springer Japan
• ISSN：1865-7265

文摘

The overexpression of mutant p53 stimulates serum p53 antibody production in patients with colorectal carcinoma even in superficial tumors. Although the short-term perioperative monitoring of serum p53 antibody titers is reported to be useful in predicting tumor recurrence and patient survival in colorectal carcinoma, the clinical utility of the long-term monitoring of serum p53 antibody titers in patients with colorectal cancer remains unknown. Here, we report the 3-year monitoring of serum p53 antibody titers in a 60-year-old man with rectal cancer, clinical stage IV (T2N2M1b, lung and liver metastases), who was treated with chemotherapy and surgery. Screening tests for CEA (29.4 ng/ml), CA19-9 (41.1 U/ml), and serum p53 antibody (2170 U/ml) were positive before treatment. After chemotherapy with mFOLFOX6 + bevacizumab (B-mab), CEA and CA19-9 decreased to the normal range. However, serum p53 antibody titer remained positive (283 U/ml). After low anterior resection, the serum p53 antibody titer still remained positive (63.4 U/ml). Serum p53 antibody titer significantly changed and was associated with treatment response and tumor recurrence. In the last 6 months of the patient’s life, serum p53 antibody titer gradually decreased, which possibly reflects the modification of the patient’s immune response to p53 antigens.